Latest Share Chat

REMOVE ADS

Skinbiotherap. Share News (SBTX)

Skinbiotherap. Information

Share Price Information for Skinbiotherap. (SBTX)

Share Price is delayed by 15 minutes

Get Live Data

11.50 0.50 (4.55%)

Bid:

11.00

Ask:

12.00

Spread: 1.00 (9.091%)

Market Cap: £29.80m

Last checked at -

Intraday Skinbiotherap. Share Chart

REMOVE ADS

Skinbiotherap. News

TRADING UPDATES: Windward extends LSEG pact; Vinanz eyes DTC trading

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

SkinBioTherapeutics reports positive interim acne study findings

(Sharecast News) - Life science company SkinBioTherapeutics reported encouraging interim findings from its ongoing AxisBiotix acne food supplement stu...

SkinBio's Dermatonics launches Once Heel Balm in Asia, ME and Africa

(Alliance News) - SkinBioTherapeutics PLC on Tuesday said its newly acquired Dermatonics will launch Pheet and Dermatonics Once Heel balm in Asia, the...

IN BRIEF: SkinBioTherapeutics up after successful year for Dermatonics

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Provides a trading update for the recently acquired D...

SkinBioTherapeutics finalises acquisition of Dermatronics

(Sharecast News) - SkinBioTherapeutics announced on Friday that it has finalised the acquisition of Dermatonics, known for its topical and dermatologi...

IN BRIEF: SkinBioTherapeutics completes Dermatonics purchase

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Completes the the acquisition of Dermatonics Ltd. On ...

IN BRIEF: SkinBioTherapeutics buys Dermatonics; in talks for 2nd deal

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Agrees to acquire Dermatonics Ltd for GBP1.7 million ...

SkinBioTherapeutics suffers acquisition delay but aims for early 2024

(Alliance News) - SkinBioTherapeutics PLC on Friday said it expects to complete an acquisition early in 2024, missing its year-end target.